Charité Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany.
STAR Protoc. 2022 Mar 10;3(1):101225. doi: 10.1016/j.xpro.2022.101225. eCollection 2022 Mar 18.
Quiescent cancer stem cells (qCSCs) are a major source of posttreatment relapse, but methods to identify molecular targets for qCSC elimination are limited. Here, we present a protocol using the fluorescent dye PKH26 to isolate label-retaining qCSCs from colorectal cancer (CRC) patient-derived organoids (PDOs). We describe processing of organoids to single cells, followed by PKH26 labeling and FACS-based cell isolation. We then detail steps for functional assays and RNA sequencing. This protocol can also be applied to normal tissue-derived organoids. For complete details on the use and execution of this protocol, please refer to Regan et al. (2021).
静止癌症干细胞 (qCSCs) 是治疗后复发的主要来源,但识别 qCSC 消除的分子靶标的方法有限。在这里,我们提出了一种使用荧光染料 PKH26 从结直肠癌 (CRC) 患者来源的类器官 (PDO) 中分离标记保留的 qCSC 的方案。我们描述了将类器官处理为单细胞,然后进行 PKH26 标记和基于 FACS 的细胞分离的过程。然后,我们详细介绍了功能测定和 RNA 测序的步骤。该方案也可应用于正常组织来源的类器官。有关此方案的使用和执行的完整详细信息,请参阅 Regan 等人。(2021 年)。